Literature DB >> 20038733

Role of axillary clearance after a tumor-positive sentinel node in the administration of adjuvant therapy in early breast cancer.

Marieke E Straver1, Philip Meijnen, Geertjan van Tienhoven, Cornelis J H van de Velde, Robert E Mansel, Jan Bogaerts, Gaston Demonty, Nicole Duez, Luigi Cataliotti, Jean Klinkenbijl, Helen A Westenberg, Huub van der Mijle, Coen Hurkmans, Emiel J T Rutgers.   

Abstract

PURPOSE The After Mapping of the Axilla: Radiotherapy or Surgery? (AMAROS) phase III study compares axillary lymph node dissection (ALND) and axillary radiation therapy (ART) in early breast cancer patients with tumor-positive sentinel nodes. In the ART arm, the extent of nodal involvement remains unknown, which could have implications on the administration of adjuvant therapy. In this preliminary analysis, we studied the influence of random assignment to ALND or ART on the choice for adjuvant treatment. PATIENTS AND METHODS In the first 2,000 patients enrolled in the AMAROS trial, we analyzed the administration of adjuvant systemic therapy. Multivariate analysis was used to assess variables affecting the administration of adjuvant chemotherapy. Adjuvant therapy was applied according to institutional guidelines. Results Of 2,000 patients, 566 patients had a positive sentinel node and were treated per random assignment. There was no significant difference in the administration of adjuvant systemic therapy. In the ALND and ART arms, 58% (175 of 300) and 61% (162 of 266) of the patients, respectively, received chemotherapy. Endocrine therapy was administered in 78% (235 of 300) of the patients in the ALND arm and in 76% (203 of 266) of the patients in the ART arm. Treatment arm was not a significant factor in the decision, and no interactions between treatment arm and other factors were observed. Multivariate analysis showed that age, tumor grade, multifocality, and size of the sentinel node metastasis significantly affected the administration of chemotherapy. Within the ALND arm, the extent of nodal involvement remained not significant in a sensitivity multivariate analysis. CONCLUSION Absence of knowledge regarding the extent of nodal involvement in the ART arm appears to have no major impact on the administration of adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20038733      PMCID: PMC2834391          DOI: 10.1200/JCO.2008.21.7554

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation.

Authors:  Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-08-22       Impact factor: 91.245

2.  The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study.

Authors:  Stella Mook; Marjanka K Schmidt; Giuseppe Viale; Giancarlo Pruneri; Inge Eekhout; Arno Floore; Annuska M Glas; Jan Bogaerts; Fatima Cardoso; Martine J Piccart-Gebhart; Emiel T Rutgers; Laura J Van't Veer
Journal:  Breast Cancer Res Treat       Date:  2008-07-27       Impact factor: 4.872

3.  Gene expression profiling predicts clinical outcome of breast cancer.

Authors:  Laura J van 't Veer; Hongyue Dai; Marc J van de Vijver; Yudong D He; Augustinus A M Hart; Mao Mao; Hans L Peterse; Karin van der Kooy; Matthew J Marton; Anke T Witteveen; George J Schreiber; Ron M Kerkhoven; Chris Roberts; Peter S Linsley; René Bernards; Stephen H Friend
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  The Cardiff-St Mary's trial.

Authors:  A P Forrest; M M Roberts; P Preece; J M Henk; H Campbell; L E Hughes; S Desai; M Hulbert
Journal:  Br J Surg       Date:  1974-10       Impact factor: 6.939

5.  Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.

Authors:  B Fisher; R G Ravdin; R K Ausman; N H Slack; G E Moore; R J Noer
Journal:  Ann Surg       Date:  1968-09       Impact factor: 12.969

6.  Operable cancer of the breast. A controlled clinical trial.

Authors:  J Bruce
Journal:  Cancer       Date:  1971-12       Impact factor: 6.860

7.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Authors:  P M Ravdin; L A Siminoff; G J Davis; M B Mercer; J Hewlett; N Gerson; H L Parker
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

8.  Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run.

Authors:  Coen W Hurkmans; Jacques H Borger; Emiel J Th Rutgers; Geertjan van Tienhoven
Journal:  Radiother Oncol       Date:  2003-09       Impact factor: 6.280

9.  A clinical trial in the management of operable cancer of the breast.

Authors:  A O Langlands; R J Prescott; T Hamilton
Journal:  Br J Surg       Date:  1980-03       Impact factor: 6.939

Review 10.  Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group.

Authors:  Emiel J T Rutgers; Philip Meijnen; Hervé Bonnefoi
Journal:  Breast Cancer Res       Date:  2004-06-16       Impact factor: 6.466

View more
  37 in total

Review 1.  Is axillary lymph node clearance required in node-positive breast cancer?

Authors:  Nigel J Bundred; Nicola L P Barnes; Emiel Rutgers; Mila Donker
Journal:  Nat Rev Clin Oncol       Date:  2014-11-04       Impact factor: 66.675

2.  Is Completion Axillary Dissection Necessary for This Patient?

Authors:  Sadullah Girgin; Atilla Soran; Nilüfer Güler; Maktav Dinçer; Gökhan Demir
Journal:  J Breast Health       Date:  2014-07-01

Review 3.  The lymph node microenvironment and its role in the progression of metastatic cancer.

Authors:  Ethel R Pereira; Dennis Jones; Keehoon Jung; Timothy P Padera
Journal:  Semin Cell Dev Biol       Date:  2015-01-22       Impact factor: 7.727

4.  A 10-year trend analysis of sentinel lymph node frozen section and completion axillary dissection for breast cancer: are these procedures becoming obsolete?

Authors:  Walter P Weber; Mitchel Barry; Michelle M Stempel; Manuela J Junqueira; Anne A Eaton; Sujata M Patil; Monica Morrow; Hiram S Cody
Journal:  Ann Surg Oncol       Date:  2011-06-07       Impact factor: 5.344

Review 5.  Is Axillary Sentinel Lymph Node Biopsy Required in Patients Who Undergo Primary Breast Surgery?

Authors:  Toralf Reimer; Jutta Engel; Marcus Schmidt; Birgitte Vrou Offersen; Marjolein L Smidt; Oreste David Gentilini
Journal:  Breast Care (Basel)       Date:  2018-08-24       Impact factor: 2.860

6.  Axillary Irradiation as an Imperative Alternative to Axillary Dissection in Clinically Lymph Node-Negative but Sentinel Node-Positive Breast Cancer Patients?

Authors:  Mirko Nitsche; Robert Hermann
Journal:  Breast Care (Basel)       Date:  2011-10-31       Impact factor: 2.860

Review 7.  Locoregional treatment of early breast cancer with isolated tumor cells or micrometastases on sentinel lymph node biopsy.

Authors:  Agnès Tallet; Eric Lambaudie; Monique Cohen; Mathieu Minsat; Marie Bannier; Michel Resbeut; Gilles Houvenaeghel
Journal:  World J Clin Oncol       Date:  2016-04-10

8.  Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial.

Authors:  T Reimer; A Stachs; V Nekljudova; S Loibl; S Hartmann; K Wolter; G Hildebrandt; B Gerber
Journal:  Geburtshilfe Frauenheilkd       Date:  2017-02       Impact factor: 2.915

9.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.

Authors:  David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Joseph P Costantino; Takamaru Ashikaga; Donald L Weaver; Eleftherios P Mamounas; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh Mc Scarth; Norman Wolmark
Journal:  Lancet Oncol       Date:  2010-10       Impact factor: 41.316

10.  Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.

Authors:  Viviana Galimberti; Bernard F Cole; Stefano Zurrida; Giuseppe Viale; Alberto Luini; Paolo Veronesi; Paola Baratella; Camelia Chifu; Manuela Sargenti; Mattia Intra; Oreste Gentilini; Mauro G Mastropasqua; Giovanni Mazzarol; Samuele Massarut; Jean-Rémi Garbay; Janez Zgajnar; Hanne Galatius; Angelo Recalcati; David Littlejohn; Monika Bamert; Marco Colleoni; Karen N Price; Meredith M Regan; Aron Goldhirsch; Alan S Coates; Richard D Gelber; Umberto Veronesi
Journal:  Lancet Oncol       Date:  2013-03-11       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.